N/A N=3 Cardioneuroablation for Neurocardiogenic Syncope
Neurocardiogenic Syncope · Vasovagal Syncope
Primary: Syncope Recurrence Rate
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=50 Syncope Decision Aid for Emergency Care
Syncope
Primary: Number of Participants at End of Study — 20; 24 Participants
Phase 2 N=129 The Effect of CPC on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope
Syncope, Vasovagal
Primary: Percentage of Participants Who Have Hypotensive Syncope or Near Syncope With SBP Less Than or Equal to 70 mmHG During Tilt Test — 32; 27; 33; 35 Participants — p=0.521
N/A N=128 Benefit of Dual-chamber Pacing With Closed Loop Stimulation (CLS) in Tilt-induced Cardioinhibitory Reflex Syncope
Syncope
Primary: Patients With Recurrence of Syncopal Episode — 10; 34 Participants — p=<0.001
Phase 4 N=210 Clinical Trial for the Prevention of Vasovagal Syncope
Syncope, Vasovagal, Neurally-Mediated
Primary: The Primary Outcome Measure Will be the Recurrence of Syncope in Follow up Period. — 42; 54 Participants
N/A N=101 Prevention of Syncope by Cardiac Pacing in Patients With Bifascicular Block
Bifascicular Block · Syncope
Primary: Combined Endpoint Defined as First Occurrence Among the Following Events 1)Syncope Episode of Any Origin; 2)Presyncopal Episode With Documented Cardioinhibitory Origin…
Phase 4 N=77 ISSUE3: International Study on Syncope of Uncertain Etiology 3
Syncope
Primary: Syncope Recurrence Rate — 57; 25 percentage of participants — p=0.04
N/A N=39 Ambulatory Post-Syncope Arrhythmia Protection Feasibility Study
Syncope
Primary: Device Unable to Monitor Due to ECG Noise — 1.5 percentage of time worn
Phase 2 N=57 Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope
Vasovagal Syncope
Primary: Number of Participants Who Become Syncopal Associated With Diagnostic Criteria of Hypotension and Bradycardia — 19; 10 Participants
Phase 2 N=40 Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)
Neurogenic Orthostatic Hypotension
Primary: Change in the OHQ (Orthostatic Hypotension Questionnaire) Composite Score — 4.61; 4.17; 3.35; 3.5 Score on a scale
N/A N=581 Applicability of Syncope Guidelines in Cataluña
Brief Loss of Consciousness
Primary: Number of Patients That Adhere to the 2009 Syncope Guidelines (ESC2009) — 233 Participants
N/A N=140 Syncope Prediction Study
Vasovagal Syncope
Primary: Sensitivity of the Syncope Prediction Algorithm — 81; 2 Participants
N/A N=40 Non-invasive Vagal Neurostimulation (nVNS) in Adolescents With Postural Orthostatic Tachycardia Syndrome (POTS)
Postural Tachycardia Syndrome · Autonomic Dysfunction · Postural Orthostatic Tachycardia Syndrome
Primary: The Change in Composite Autonomic Symptom Score (COMPASS-31) — -5.40; -5.94 score on a scale
Phase 4 N=24 Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension
Hypotension, Orthostatic
Primary: Time to Onset of Near-syncopal Symptoms During Tilt Table Testing — 551.3; 461.0 seconds — p=0.1460
Phase 3 N=350 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)
Primary Autonomic Failure · Dopamine Beta Hydroxylase Deficiency · Non-Diabetic Neuropathy
Primary: Patients With Treatment-emergent Adverse Events — 263 participants
N/A N=86 Diagnostic Yield of an Ambulatory Patch Monitor in Unexplained Emergency Department Syncope: A Pilot Study (PATCH-ED)
Syncope
Primary: Number of Ambulatory Patch Monitor Participants Having Significant Symptomatic Arrhythmia — 9 Participants
Phase 2 N=6 Intravenous Norepinephrine for Orthostatic Hypotension
Orthostatic Hypertension
Primary: Blood Pressure (Systolic) — 156; 158; 179; 148 mm Hg
N/A N=26 Gastrointestinal Symptoms in Postural Orthostatic Tachycardia Syndrome
Postural Tachycardia Syndrome
Primary: C-peptide Levels After Oral Glucose Tolerance Test — 40.6; 23.2 pg/mL
Phase 4 N=87 Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study
Orthostatic; Hypotension, Neurogenic
Primary: Change in Orthostatic BP Drop — 11.1; 13.6; 8.9; 7.5 mmHg
N/A N=20 Head-up Tilt Test in Patients With Reflex Syncope and Asystolic Response Who Received a Dual-chamber Pacemaker With the Closed Loop Stimulation (CLS) and Participated in the BIOSync Trial
Syncope · Syncope, Vasovagal
Primary: Heart Rate [Bpm] at Specific Time-points During Head-up Tilt Test (HUTT) Examination — 70; 88; 105; 95 beats per minute
N/A N=1 Optimization of VNS in Epileptic Patients to Induce Cardioprotection
Epilepsy · Sudden Cardiac Death
Primary: Change in Seizure Frequency or Duration Via a Routine Seizure History Used in Clinical Practice.
N/A N=112 Neuroprotective Goal Directed Hemodynamic Optimization in Post-cardiac Arrest Patients
Cerebral Ischemia · Cardiac Arrest
Primary: % of Ischaemic Voxels With an ADC<0.65 mm2/s on Day 4-5 (Diffusion Weighted MRI) — 10.6; 11.0 percentage of ischaemic voxels — p=0.0881
Phase 3 N=181 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
Symptomatic Neurogenic Orthostatic Hypotension (NOH) · Non-diabetic Neuropathy · Primary Autonomic Failure
Primary: Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1) — 1.3; 1.9 units on a scale — p=0.509
Phase 3 N=26 Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome
Primary: Change in Heart Rate — 17.0; 13.1 beats per minute
N/A N=47 Auricular Neurostimulation for Cyclic Vomiting Syndrome
Cyclic Vomiting Syndrome · Abdominal Migraine
Primary: Rhodes Index of Nausea, Vomiting & Retching (INVR) — 3.25; 5.80; 10.43; 0.75 score on a scale
N/A N=49 Non-invasive Vagal Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients With Gastroparesis and Related Disorders
Chronic Unexplained Nausea and Vomiting · Gastroparesis
Primary: Average Daily Use of Rescue Medications for Exacerbation of Nausea/Vomiting. — 1.186; 0.551; 0.754; 0.447 medications/day
Phase 4 N=453 Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
Symptomatic Neurogenic Orthostatic Hypotension
Primary: Time To Intervention — 52.00; 42.00; NA; NA Days — p=0.803
Phase 3 N=263 A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa
Symptomatic Neurogenic Orthostatic Hypotension (NOH) · Non-diabetic Neuropathy · Primary Autonomic Failure
Primary: Change in Orthostatic Hypotension Questionnaire Score (OHQ) — -1.83; -0.93 units on a scale — p=0.003
N/A N=17 Evaluating the Influence of Apnea on Cardiac Function Using Cardiac Magnetic Resonance Imaging.
Physiological Changes in Deliberate Apnea
Primary: Cardiac Function: Duration of Apnea — 483 sec
Phase 3 N=103 Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
Neurogenic Orthostatic Hypotension · Non-Diabetic Autonomic Neuropathy · Multiple System Atrophy
Primary: Change in Orthostatic Hypotension Questionnaire Composite Score (OHQ) — 0.57; 0.90 units on a scale — p=0.438